Article Details
Retrieved on: 2018-02-28 02:31:59
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
<div>Finally, <b>Vanguard Group</b> Inc. increased its holdings in shares of Aimmune Therapeutics by 12.6% in the 2nd quarter. <b>Vanguard Group</b> Inc. now owns 2,476,836 shares of the biotechnology company's stock worth $50,923,000 after purchasing an additional 276,978 shares in the last quarter. Institutional ...</div>
Article found on:
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here